Back to today’s briefing

Story perspectives

New Drug 32-134D Offers Hope for Diabetic Retinopathy

6/10/2025

31 7

Summary

Story summary

A groundbreaking experimental drug, 32-134D, is on the horizon to fight diabetic retinopathy, a leading cause of vision loss. By blocking hypoxia inducible factor (HIF), this innovative treatment shows promise in safeguarding retinal cells from the ravages of low blood sugar. Exciting clinical trials are set to begin soon, offering hope to many.

1 of 1

Story summary

A groundbreaking experimental drug, 32-134D, is on the horizon to fight diabetic retinopathy, a leading cause of vision loss. By blocking hypoxia inducible factor (HIF), this innovative treatment shows promise in safeguarding retinal cells from the ravages of low blood sugar. Exciting clinical trials are set to begin soon, offering hope to many.